JNCE Jounce Therapeutics

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that its scientific founder, Dr. James P. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine for the discovery of cancer therapy by inhibition of negative immune regulation.

“On behalf of the whole Jounce team, I want to take the opportunity to congratulate Jim on this historic recognition and honor. Since our founding, Jounce has benefited tremendously from his leadership, expertise and dedication to cancer immunotherapy and this award is a testament to all that he has accomplished,” said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. “Jim played a fundamental role in ushering in the era of cancer immunotherapy, including his contributions to the understanding of the basic science of CTLA-4. Additionally, the identification of ICOS as a therapeutic approach in immuno-oncology led to the discovery and development of Jounce’s lead product candidate, JTX-2011.”

Additional information regarding Dr. James P. Allison’s biography and award can be found .

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently conducting the Phase 1/2 ICONIC trial. For more information, please visit

Investor Contact:

Komal Joshi

Jounce Therapeutics, Inc.

(857) 320-2523

Media Contact:

Gina Nugent

The Yates Network

(617) 460-3579

EN
01/10/2018

Underlying

JNCEJounce Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Jounce Therapeutics

 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 03-Apr-2023 / 12:25 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trus...

April 3, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Termination of Proposed Business Combination of Jounce Therapeutics, I...

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the ...

April 3, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 30-March-2023 / 13:21 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the tr...

March 30, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 29-March-2023 / 13:22 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the tr...

March 29, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 28-March-2023 / 13:33 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the tr...

March 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch